Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-21-060749
Filing Date
2021-10-18
Accepted
2021-10-18 18:44:19
Documents
1
Period of Report
2021-10-14

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4382
  Complete submission text file 0001209191-21-060749.txt   5724
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
KAKKIS EMIL D (Reporting) CIK: 0001248093 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36276 | Film No.: 211329189

Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Issuer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations